No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Thursday, October 23, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

by TheAdviserMagazine
3 weeks ago
in Business
Reading Time: 3 mins read
A A
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Share on FacebookShare on TwitterShare on LInkedIn


Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.

Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

When a lesser degree of weight loss is required, other medications can be considered, including liraglutide, an older, less effective drug from the same class, naltrexone-bupropion, and phentermine-topiramate, the guideline says. The EASO guidelines are non-binding on individual countries.

Semaglutide, tirzepatide, and other drugs from the class known as GLP-1 agonists are completely transforming care of obesity and its complications, coauthor Dr. Andreea Ciudin of Vall d’Hebron University Hospital in Barcelona said in a statement.

Live Events

Although no treatment algorithm can replace the nuanced clinical judgment necessary for comprehensive patient care, the new guidelines can serve to support therapeutic decision-making in obesity, she said.

SPECIFIC DRUGS FOR SPECIFIC CONDITIONS

The guideline authors analyzed previous clinical trial results, evaluating the impact of medications on weight loss, their safety profile, and their effectiveness in the presence of specific complications. For patients with the physical consequences of too much fatty, or adipose, tissue, tirzepatide should be considered as the first-line treatment for addressing obstructive sleep apnea, and semaglutide for those with knee osteoarthritis, the authors determined.

For patients with conditions linked with obesity-related metabolic and immune dysfunction, they recommend semaglutide as a first choice for those with a history of heart disease or stroke, tirzepatide for individuals with non-alcoholic fatty liver disease, and either tirzepatide or semaglutide for those with prediabetes or type 2 diabetes.

The class of drugs was originally developed to treat type 2 diabetes.

While the drugs are expensive and economic considerations are complex, the cost of not treating obesity at early stages, “thus enabling the progression to complications and end-organ damage, should be weighed equally in health policy and clinical decision-making,” the guideline authors wrote.

The management of obesity should not be limited to weight loss and its complications but should focus on enhanced mental well-being, physical fitness, social functioning, and overall health and quality of life as well, they also said.

Most of the newer medications have not been evaluated for the treatment of individual complications, they acknowledge.

Still, the authors say, the weight-loss effects have been strongly associated with improvements in various complications and there is growing potential for them to positively influence a broader range of disorders such as chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, certain cancers, and mental health conditions.

“Given the rapid advances in the field of medications to treat obesity, EASO intends to update the present treatment algorithm regularly to incorporate the latest available evidence,” society President Professor Volkan Yumuk of Istanbul University-Cerrahpaşa said in a statement.

The American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society jointly advised in June that GLP-1 treatment must be accompanied by nutritional and lifestyle strategies.

“Although GLP‐1s alone can produce significant weight reduction and related health benefits, several challenges limit its long‐term success for individuals and populations,” including gastrointestinal side effects, risk of nutrient inadequacies, muscle and bone loss, high costs, frequent discontinuation, and weight regain,” the advisory said.

Add ET Logo as a Reliable and Trusted News Source



Source link

Tags: doctorsdrugsEuropeanLillyNovoobesityoptionTreatmentsWeightLoss
ShareTweetShare
Previous Post

What CEOs are saying about the government shutdown

Next Post

PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

Related Posts

edit post
NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

by TheAdviserMagazine
October 23, 2025
0

 Zohran Mamdani was attacked over his thin resume, Republican Curtis Sliwa strove to prove his seriousness as a candidate and...

edit post
Corporate debt surge: Commercial paper issuances hit highest since April

Corporate debt surge: Commercial paper issuances hit highest since April

by TheAdviserMagazine
October 23, 2025
0

Indian companies increased their reliance on the debt money market for their short-term working capital needs with the issuance value...

edit post
Israeli joint venture wins huge Indian army rifle deal

Israeli joint venture wins huge Indian army rifle deal

by TheAdviserMagazine
October 23, 2025
0

The Indian Army is procuring 425,000 CQB carbine assault rifles from PLR Systems, a joint venture between Israel Weapons...

edit post
Stock Market Today: Dow Jones Index Gains As Tesla Dives On Earnings (Live)

Stock Market Today: Dow Jones Index Gains As Tesla Dives On Earnings (Live)

by TheAdviserMagazine
October 23, 2025
0

The Dow Jones Industrial Average and the other major stock indexes reversed from premarket losses and ventured into positive ground...

edit post
United Bankshares GAAP EPS of alt=

United Bankshares GAAP EPS of $0.92 beats by $0.11, revenue of $323.32M beats by $13.52M

by TheAdviserMagazine
October 23, 2025
0

United Bankshares press release (NASDAQ:UBSI): Q3 GAAP EPS of $0.92 beats by $0.11. Revenue of $323.32M (+23.3% Y/Y) beats by...

edit post
U.S. national debt hits  trillion and Washington is ‘numb to our own dysfunction,’ budget committee warns

U.S. national debt hits $38 trillion and Washington is ‘numb to our own dysfunction,’ budget committee warns

by TheAdviserMagazine
October 23, 2025
0

America’s debt burden has hit $38 trillion. In fact, at the time of writing, it is $19 billion over that...

Next Post
edit post
PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

PepsiCo's new challenge: Making its chips and sodas colorful without artificial dyes

edit post
Axis Securities gives Nifty target of 25,500, names Bharti Airtel and Lupin among top 15 picks

Axis Securities gives Nifty target of 25,500, names Bharti Airtel and Lupin among top 15 picks

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

October 9, 2025
edit post
2025 Healthcare Stocks List | Updated Daily

2025 Healthcare Stocks List | Updated Daily

0
edit post
Post-Pandemic Inflation In Canada | Armstrong Economics

Post-Pandemic Inflation In Canada | Armstrong Economics

0
edit post
Glassnode identifies concentrated Bitcoin selling amid market consolidation

Glassnode identifies concentrated Bitcoin selling amid market consolidation

0
edit post
Why The Smartest Are Not The Richest

Why The Smartest Are Not The Richest

0
edit post
Shell: Energieriese nach monatelanger Seitwärtsphase im Aufwind!

Shell: Energieriese nach monatelanger Seitwärtsphase im Aufwind!

0
edit post
Corporate debt surge: Commercial paper issuances hit highest since April

Corporate debt surge: Commercial paper issuances hit highest since April

0
edit post
Glassnode identifies concentrated Bitcoin selling amid market consolidation

Glassnode identifies concentrated Bitcoin selling amid market consolidation

October 23, 2025
edit post
NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

October 23, 2025
edit post
Why The Smartest Are Not The Richest

Why The Smartest Are Not The Richest

October 23, 2025
edit post
Corporate debt surge: Commercial paper issuances hit highest since April

Corporate debt surge: Commercial paper issuances hit highest since April

October 23, 2025
edit post
UK startup Mondra lands €11.4M to help food industry manage climate and supply chain volatility

UK startup Mondra lands €11.4M to help food industry manage climate and supply chain volatility

October 23, 2025
edit post
2025 Healthcare Stocks List | Updated Daily

2025 Healthcare Stocks List | Updated Daily

October 23, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Glassnode identifies concentrated Bitcoin selling amid market consolidation
  • NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’
  • Why The Smartest Are Not The Richest
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.